# A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

> **NCT04019327** · PHASE1,PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Prostate Cancer
- Prostate Adenocarcinoma
- Prostate Neoplasm
- Prostate Cancer Metastatic
- Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Talazoparib
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04019327
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-11
- **Primary completion:** 2025-12-04
- **Final completion:** 2025-12-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04019327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04019327, "A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04019327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*